Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HeartBeam, Inc.BEAT · Entity 9039 | President | April 16, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HeartBeam, Inc.
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,742 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Purchase · Acquired 12,500 · Balance 36,742 F1: These shares were purchased in connection with the Registrant's underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for the offering, which priced on April 14, 2026, and closed on April 16, 2026. F2: Includes 23,333 RSUs which have vested as per the Form 4 filed on October 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased in connection with the Registrant's underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for the offering, which priced on April 14, 2026, and closed on April 16, 2026.
F2: Includes 23,333 RSUs which have vested as per the Form 4 filed on October 2, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 17, 2026 00:47 UTC | HeartBeam, Inc. BEAT · Entity 9039 | PurchaseCommon Stock | 12,500 | $0.80 | $10,000.00 |
DisclosureSEC source: 0001213900-26-044834 · ownership.xml · nonDerivative · entry 1 ENO Robert Paul · CIK 0001963418 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,742 F1 · shares: These shares were purchased in connection with the Registrant's underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for the offering, which priced on April 14, 2026, and closed on April 16, 2026. F2 · balance_after: Includes 23,333 RSUs which have vested as per the Form 4 filed on October 2, 2025. Read SEC document |
| February 09, 2026 Filed Mar 23, 2026 21:29 UTC | HeartBeam, Inc. BEAT · Entity 9039 | GrantCommon Stock (right to buy) · Derivative | 55,172 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001213900-26-033021 · ownership.xml · derivative · entry 1 ENO Robert Paul · CIK 0001963418 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,172 Underlying: Common Stock · 55,172 shares Expires 2036-01-01 F1 · derivative.exercise_date: Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan. Read SEC document |
| April 07, 2025 Filed May 1, 2025 15:05 UTC | HeartBeam, Inc. BEAT · Entity 9039 | GrantStock option (right to buy) · Derivative | 320,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001213900-25-038173 · ownership.xml · derivative · entry 1 ENO Robert Paul · CIK 0001963418 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,000 Underlying: Common Stock · 320,000 shares Expires 2035-04-07 F1 · derivative.exercise_date: Granted 320,000 options on April 7, 2025, which are scheduled to vest over 4 years with 25% vesting on April 7, 2025, and the remainder vesting and exercisable monthly thereafter. These options have been issued from the Company's 2022 Equity Incentive Plan. Read SEC document |
| August 02, 2023 Filed Aug 5, 2023 01:41 UTC | HeartBeam, Inc. BEAT · Entity 9039 | GrantStock option (right to buy) · Derivative | 357,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001213900-23-063795 · ownership.xml · derivative · entry 1 ENO Robert Paul · CIK 0001963418 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,000 Underlying: Common Stock · 357,000 shares Expires 2033-08-02 F1 · shares: The options ("Option" and collectively, "Options") have been issued from the Company's 2022 Equity Incentive Plan, that was approved by the Members of the Board of Directors on August 1, 2023. F2 · derivative.exercise_date: The Options will vest and become exercisable with respect to 40% of the shares starting August 1, 2023, with one forty-eighth (1/48th) of the shares vesting each calendar month thereafter on the same day of the month as the first vesting date. The remaining 60% of the shares will vest and become exercisable once HeartBeam, Inc. receives FDA Clearance for marketing of HeartBeam's synthesized 12-Lead product obtained by signal synthesis from the recorded xyz signals. Read SEC document |
| May 14, 2023 Filed Jun 10, 2023 00:02 UTC | HeartBeam, Inc. BEAT · Entity 9039 | GrantStock option (right to buy) · Derivative | 179,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001779372-23-000018 · wk-form4_1686355324.xml · derivative · entry 1 ENO Robert Paul · CIK 0001963418 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,000 Underlying: Common Stock · 179,000 shares Expires 2033-05-13 F1 · derivative.exercise_price: The exercise price per share of each option (?Option? and collectively, the ?Options?) shall be the Fair Market Value (as defined in the Company?s 2022 Equity Incentive Plan) of a share as of May 14, 2023. F2 · shares: The Options have been issued from the Company's 2022 Equity Incentive Plan, that was approved by the Members of the Board of Directors on May 14, 2023. F3 · derivative.exercise_date: The Options will vest and become exercisable with respect to 40% of the shares starting May 14, 2023, with one forty-eighth (1/48th) of the shares vesting each calendar month thereafter on the same day of the month as the first vesting date. The remaining 60% of the shares will vest and become exercisable once HeartBeam, Inc. receives FDA Clearance for marketing of HeartBeam?s synthesized 12-Lead product obtained by signal synthesis from the recorded xyz signals. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.